
News|Articles|April 1, 2003
Inhaled corticosteroids may carry less risk of BMD reduction in postmenopausal women
Corticosteroid therapy is an effective treatment for asthma sufferers, but the use of systemic corticosteroids is known to increase the risk of osteoporotic fractures. A recent study published in the Journal of Allergy and Clinical Immunology suggests that moderate doses of inhaled corticosteroids (ICs) carry less risk than traditional oral corticosteroid (OC) therapy with respect to reduction of bone mineral density (BMD) in postmenopausal women. This assertion is based on the premise that the lowest daily dose of IC sufficient to control the patient's asthma is used.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
2
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Healthcare’s workforce has a scale problem, but new model is emerging
5


























